Oxaliplatin in non-seminomatous germ-cell tumors
Open Access
- 1 August 2004
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 15 (8) , 1295
- https://doi.org/10.1093/annonc/mdh307
Abstract
Recently, Kollmannsberger et al. [1] reported the final results of a phase II trial of oxaliplatin as a single agent in patients with relapsed or refractory non-seminomatous germ-cell tumors (NSGCT) treated from 1998 to 2001. The authors concluded that oxaliplatin is an active agent and that it should be evaluated in combination regimens.Keywords
This publication has 6 references indexed in Scilit:
- Combination Chemotherapy With Gemcitabine Plus Oxaliplatin in Patients With Intensively Pretreated or Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study GroupJournal of Clinical Oncology, 2004
- Activity of Oxaliplatin in Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study GroupJournal of Clinical Oncology, 2002
- Phase I, Dose-Finding, and Pharmacokinetic Study of Raltitrexed Combined With Oxaliplatin in Patients With Advanced CancerJournal of Clinical Oncology, 2000
- Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patientsZeitschrift für Krebsforschung und Klinische Onkologie, 1999
- Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancerEuropean Journal Of Cancer, 1997
- Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panelBiochemical Pharmacology, 1996